An Exploratory Clinical Study Evaluating the Efficacy and Safety of Tunlametinib Combined With Fruquintinib in the Third-line Treatment of Advanced Colorectal Cancer Patients With RAS Mutations.

This study is a prospective, open-label, single-arm clinical study aimed at evaluating the efficacy and safety of Tunlametinib combined with Fruquintinib in the third-line treatment of advanced colorectal cancer patients with RAS mutations.

NCT Number	NCT06985316
Lead Sponsor	Liu Huang
Conditions	CRC, Colorectal Cancer
Enrollment	34 participants
Start Date	2025-05-19
Primary Completion	2028-04-27 (estimated)
Study Completion	2028-04-27 (estimated)
Updated on ClinicalTrials.gov	2025-05-22